Molecular biology of angiotensin receptors and their role in human cardiovascular disease. 1996

V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
Department of Internal Medicine/Cardiology, Virchow-Klinikum, Humboldt Universität, Berlin, Germany.

The actions of angiotensin II in the cardiovascular system are transmitted by two known and possibly some unknown angiotensin receptor types. AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site. Cloning of coding regions and promoter sequences contributed to the understanding of receptor protein function and regulation. Angiotensin receptors with atypical binding properties for the known AT1- and AT2-specific ligands are expressed on human cardiac fibroblasts and in the human ulcrus. In several animal models, receptors with high affinity for angiotensin (1-7) have been described. AT1 stimulation is mediated by the generation of phospholipid-derived second messengers, activation of protein kinase C, the MAPkinase pathway and of immediate early genes. Recently, phosphorylation and dephosphorylation of tyrosine kinases have been associated with AT1- and AT2-mediated signal transduction. ATR are regulated by phosphorylation, internalization, modification of transcription rate and mRNA stability. Regulation is highly cell and organ specific and includes upregulation of ATR in some pathophysiological situations where the renin angiotensin system is activated. Whereas the function of AT1 in the cardiovascular system is relatively well established, there is little information regarding the role of AT2. Recent hypotheses suggest an antagonism between AT1 and AT2 at the signal transduction and the functional level. Transgenic animal models, particularly with targeted disruption of the AT1 and AT2 genes, suggest the contribution of both genes to blood pressure regulation. Genetic polymorphisms have been described in the AT1 and AT2 gene or neighbored regions and are used to analyze the association between gene defects and cardiovascular diseases. AT1 antagonists are now being introduced into the treatment of hypertension and potentially heart failure, and more interesting pharmacological developments are expected from the ongoing basic studies.

UI MeSH Term Description Entries
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
July 1999, Clinical and experimental pharmacology & physiology,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
January 1991, Journal of cardiovascular pharmacology,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
January 2014, Advances in clinical chemistry,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
August 1995, The Canadian journal of cardiology,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
May 1993, Circulation,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
January 1999, Journal of the American Society of Nephrology : JASN,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
December 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
January 1995, Trends in cardiovascular medicine,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
July 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
V Regitz-Zagrosek, and M Neuss, and J Holzmeister, and C Warnecke, and E Fleck
December 1998, Indian journal of experimental biology,
Copied contents to your clipboard!